Skip to main content

The Globe and Mail

Directors buying after ImmunoVaccine surges on early December news

Directors buying ImmunoVaccine

iStockPhoto

ImmunoVaccine Inc. is almost about 75 per cent over the past six months. The stock got a boost from recent news including a Dec. 7 announcement that it would be expanding collaboration with UConn Health on its DPX-NEO program which aims to develop patient-specific immunotherapies targeting neoepitopes. Since Christmas, two directors bought a total of 30,000 shares in the market as the stock pulled back from its highs. Generally, it can be a positive sign to see insiders buying when a stock is up after news.

Ted Dixon is CEO of INK Research which provides insider news and knowledge to investors. For more background on insider reporting in Canada, visit the FAQ section at www.inkresearch.com. Securities referenced in this profile may have already appeared in recent reports distributed to INK subscribers. INK staff may also hold a position in profiled securities.

Chart reflects public-market transactions of common shares or unit trusts by company officers and directors.

Story continues below advertisement

Report an error Editorial code of conduct
As of December 20, 2017, we have temporarily removed commenting from our articles. We hope to have this resolved by the end of January 2018. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.